dc.creator | Moreno Márquez, Carolina | es |
dc.creator | Fernández Álvarez, Paula | es |
dc.creator | Castro Laria, Luisa | es |
dc.creator | Argüelles Arias, Federico | es |
dc.creator | Caunedo Álvarez, Ángel | es |
dc.creator | Gómez Rodríguez, Blas José | es |
dc.date.accessioned | 2024-04-29T17:52:05Z | |
dc.date.available | 2024-04-29T17:52:05Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Moreno Márquez, C., Fernández Álvarez, P., Castro Laria, L., Argüelles Arias, F., Caunedo Álvarez, Á. y Gómez Rodríguez, B.J. (2022). Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori. Revista Española de Enfermedades Digestivas, 114 (2), 89-955. https://doi.org/10.17235/reed.2021.7931/2021. | |
dc.identifier.issn | 1130-0108 | es |
dc.identifier.issn | 2340-4167 | es |
dc.identifier.uri | https://hdl.handle.net/11441/157293 | |
dc.description.abstract | Introduction: the primary goal of this study was to com pare gastrointestinal symptom reduction in patients on
bismuth-containing quadruple eradication therapy sup plemented with Lactobacillus reuteri strains (DSM 17938
and ATCC PTA 6475) or placebo.
Materials and methods: this was a randomized, dou ble-blind, parallel-arm, placebo-controlled clinical trial.
Patients received a first-line eradication regimen based on
bismuth subcitrate potassium, metronidazole, tetracycline
hydrochloride (three-in-one capsules) and omeprazole 40
mg twice a day for ten days, plus a probiotic or placebo
tablet for 30 days. During follow-up, gastrointestinal symp toms were assessed using an evaluation scale (GSRS), and
adverse events were collected at 0, 14, 28 and 56 days.
Results: a total of 80 patients were included from Febru ary 2018 to May 2019 at a single site. Eradication thera py was effective in 85 % of patients, with no differences
between treatment arms. In the group receiving the probi otic, abdominal pain decreased in 42 % of patients, com pared with 19 % in the control group (OR: 0.27; CI, 0.13-0.58;
p < 0.001), and abdominal distension decreased in 25 %
versus 17 % in the control group (OR: 0.24; IC, 0.19-0.84;
p < 0.001);
Conclusions: treatment with L. reuteri only reduced
abdominal pain and distension. Further studies are needed to establish the role of probiotics as adjuvant therapy in
H. pylori eradication. | es |
dc.format | application/pdf | es |
dc.format.extent | 7 p. | es |
dc.language.iso | eng | es |
dc.publisher | Aran Ediciones S.A. | es |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 114 (2), 89-955. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Helicobacter | es |
dc.subject | Lactobacillus | es |
dc.subject | Eradication | es |
dc.subject | Probi otics | es |
dc.subject | Bismuth | es |
dc.subject | Quadruple | es |
dc.title | Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.reed.es/ArticuloFicha.aspx?id=5983&hst=0&idR=105&tp=1 | es |
dc.identifier.doi | 10.17235/reed.2021.7931/2021 | es |
dc.journaltitle | Revista Española de Enfermedades Digestivas | es |
dc.publication.volumen | 114 | es |
dc.publication.issue | 2 | es |
dc.publication.initialPage | 89 | es |
dc.publication.endPage | 955 | es |